Article
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
Science (New York, N.Y.) - 27 Sept 1991
St Clair M H, Martin J L, Tudor-Williams G, Bach M C, Vavro C L, King D M, Kellam P, Kemp S D, Larder B A
Abstract excerpt
Serial human immunodeficiency virus type-1 (HIV-1) isolates were obtained from five individuals with acquired immunodeficiency syndrome (AIDS) who changed therapy to 2',3'-dideoxyinosine (ddI) after at least 12 months of treatment with 3'-azido-3'-deoxythymidine (zidovudine, AZT). The in vitro sensitivity to ddI decreased during the 12 months following ddI initiation, whereas AZT sensitivity increased. Analysis...
Topics
- Acquired Immunodeficiency Syndrome
- Base Sequence
- DNA, Viral
- Didanosine
- Drug Resistance, Microbial
- Genotype
- HIV-1
- Humans
- Molecular Sequence Data
- Mutation
- Oligodeoxyribonucleotides